Daily low-dose aspirin does not prevent cognitive decline in healthy older adults PRESS RELEASE: 1st...
Researchers
ASPREE’s Australian award trifecta
Impact of ASPREE trial on public health recognised We are pleased to share three Australian research...
NIH funds ASPREE-XT (eXTension) study
Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly PRESS RELEASE ...
Researchers from National Cancer Institute (NCI) visit ASPREE
A welcome to Melbourne Australian ASPREE investigators welcomed members from the National Cancer Institute...
US heart specialists pen importance of ASPREE trial to clinicians
The ASPREE Aftermath: A Geriatric Perspective on the Role of Aspirin in Older Adults Thanks to...
ASPREE publishes trial results in New England Journal of Medicine today!
Daily low-dose aspirin doesn't reduce heart-attack risk in healthy people For decades, doctors have been prescribing...
UK aspirin study on GI bleeding
Daily aspirin users might need a PPI Elderly patients taking daily aspirin after a stroke or MI (heart...
ASPREE investigator reflects on public-good clinical trials
Prof Chris Reid shares 30 years experience in medical research Professor Chris Reid is a Director of the Monash...
ASPREE international researcher meet-up
Earlier this month we welcomed our U.S. research collaborators from the Berman Center for Outcomes and Clinical...
NHMRC Funding Boost for Australia’s Largest Clinical Aspirin Trial
Australian Government funding for ASPREE Completion The ASPREE Clinical Trial received more than $5.5 million...